ACTG
A5247
(Opening Soon)
Study Drugs
At study entry, subjects will be randomized 3:1 to the following groups:
Vaccine group: ZOSTAVAX at Day 0 and Week 6
Placebo group: Placebo at Day 0 and Week 6
Eligibility Criteria
Virologically suppressed on potent combination ART and CD4+ T-cell count >=200 cells/mm3.
Contact
Graham
Ray ,
RN, MSN (303) 724-0712
Return to HOME